Biotech Values

[apljack]

Not to throw any cold water on NEU, but their use of a CABG population is a poor choice, given the metrics of cognitive change during and after the acute recovery phase of the surgery. NEU would be much smarter to convince the DOD to sponsor a larger trial with vets and/or one of the many existing populations of ABI patients, or choose another population where big difference(s) can be made, like acute stroke patients.

I've never posted here before, but work as a neuropsychologist in this area and have had a hand in many previous neuroprotection trials for AD and Vascular dementia. Reading NEU's information regarding glypromate was not very impressive to me.

regard

aj